SLU-PP-915 Capsules
SLU-PP-915 Capsules USA — Capsules
Pan-ERR Agonist
SLU-PP-915 is a synthetic small molecule developed as an agonist of the estrogen-related receptors (ERRα, ERRβ and ERRγ), a family of orphan nuclear receptors. It is supplied for laboratory research only and has been characterised in controlled experimental systems.
This product is intended strictly for laboratory research use within the United States. It is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable U.S. federal, state, and local regulations.
SLU-PP-915 is a synthetic small molecule developed as an agonist of the estrogen-related receptors (ERRα, ERRβ and ERRγ), a family of orphan nuclear receptors. It is supplied for laboratory research only and has been characterised in controlled experimental systems.
In the published literature, SLU-PP-915 has been examined in medicinal chemistry work defining its potency across the three ERR isoforms, in rodent models of cardiac metabolism and exercise capacity, and in in vitro metabolism studies characterising the compound for analytical detection purposes.
Third-party tested for purity, ID, quantity.
Coming Soon
The certificate of analysis for this lot is being finalised and will be published here as soon as the lab returns it.
SLU-PP-915 belongs to a chemical series of pan-ERR agonists developed from earlier compounds in the SLU-PP scaffold. The estrogen-related receptors act as constitutively active transcription factors regulating genes associated with mitochondrial biogenesis, oxidative phosphorylation and fatty acid handling. SLU-PP-915 was identified during structure-activity work on this series and reported as a potent agonist across ERRα, ERRβ and ERRγ with oral exposure in rodents.
Research endpoints evaluated to date include ERR isoform potency and selectivity in cell-based reporter assays, transcriptional readouts related to mitochondrial and fatty acid oxidation gene programmes, cardiac function and substrate metabolism in rodent heart failure models, and aerobic exercise capacity in rodents. Separate analytical work has characterised its in vitro metabolic profile and candidate metabolites, framed around detection in anti-doping contexts.
SLU-PP-915 emerged from a medicinal chemistry programme aimed at improving on earlier pan-ERR agonists in the same series. A 2023 report described the development and pharmacological evaluation of the new chemical series and identified SLU-PP-915 as the lead compound, with improved potency relative to its predecessors.
Subsequent publications extended the record into disease and physiology models, including rodent heart failure studies examining cardiac fatty acid metabolism and mitochondrial function, and a later report on orally administered SLU-PP-915 in rodent aerobic exercise capacity models. The compound also appears in review coverage of nuclear receptor modulators and of pharmacological ERR activation as an exercise-mimetic research concept, and in analytical chemistry work establishing its metabolite profile. The published record remains small and consists largely of preclinical and in vitro work; no human clinical data were identified in the available references.
Laboratory investigations into SLU-PP-915 centre on pharmacological activation of the ERRα/β/γ nuclear receptor family. Research frameworks include cell-based receptor potency and selectivity assays, transcriptional profiling of mitochondrial and fatty acid oxidation gene programmes, rodent cardiac models evaluating substrate metabolism and mitochondrial function under heart failure conditions, rodent exercise capacity models used to explore exercise-mimetic pharmacology, and in vitro metabolism studies supporting analytical detection method development.
5 of the 5 areas below are addressed directly by a paper cited on this page.
Pan-ERR nuclear receptor agonism
Addressed on this page by Di 2026, Billon 2026. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Di, Giovanni C. et al. (2026) — Nuclear Receptor-Targeted Therapies: Reprogramming Metabolism with TRβ, ERRα, and LXR Modulators
- Billon, C. et al. (2026) — An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity
Mitochondrial biogenesis and oxidative metabolism models
Addressed on this page by Xu 2024, Möller 2026, Di 2026. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Xu, W. et al. (2024) — Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function
- Möller, T. et al. (2026) — In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential
- Di, Giovanni C. et al. (2026) — Nuclear Receptor-Targeted Therapies: Reprogramming Metabolism with TRβ, ERRα, and LXR Modulators
Rodent cardiac fatty acid metabolism and heart failure models
Addressed on this page by Xu 2024, Möller 2026, Di 2026. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Xu, W. et al. (2024) — Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function
- Möller, T. et al. (2026) — In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential
- Di, Giovanni C. et al. (2026) — Nuclear Receptor-Targeted Therapies: Reprogramming Metabolism with TRβ, ERRα, and LXR Modulators
Exercise capacity and exercise-mimetic research
Addressed on this page by Billon 2026, de 2026. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Billon, C. et al. (2026) — An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity
- de, Souza-Lima J. et al. (2026) — [Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications]
In vitro metabolism and analytical characterisation
Addressed on this page by Möller 2026, Xu 2024, Di 2026. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Möller, T. et al. (2026) — In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential
- Xu, W. et al. (2024) — Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function
- Di, Giovanni C. et al. (2026) — Nuclear Receptor-Targeted Therapies: Reprogramming Metabolism with TRβ, ERRα, and LXR Modulators
The references section of this page cites 6 primary papers published between 2023 and 2026 — a limited but non-trivial record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
SLU-PP-915 Capsules is frequently listed as a peptide by suppliers in this market. It is not one. The structure published on this page is the compound's actual chemistry, and research on it should be read against its own class rather than against peptide literature.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for SLU-PP-915 Capsules, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
SLU-PP-915 Capsules is commonly described online in connection with weight loss, appetite suppression and fat reduction. In the research literature the same compound is filed under pan-ERR nuclear receptor agonism, mitochondrial biogenesis and oxidative metabolism models and rodent cardiac fatty acid metabolism and heart failure models.
The 6 papers cited on this page, published between 2023 and 2026 describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Every lot of SLU-PP-915 Capsules is independently assayed before it is released, and the certificate for the lot shipped is published rather than summarised. Where a certificate for a current lot is not yet posted, the lot has not yet been released against it.
Researchers who buy SLU-PP-915 Capsules in the United States through Eppix Labs receive a batch-labelled vial whose certificate is published against that lot code, so the material can be matched to its analysis rather than to a generic specification.
- Storage
- Cool, dry, away from direct light
- Humidity
- Keep sealed; capsule shells are hygroscopic
- Reconstitution
- Not applicable — supplied pre-measured
- Format
- Oral capsule
SLU-PP-915 Capsules is supplied in capsule form, which removes the reconstitution step entirely: there is no vehicle to add, no reconstitution volume to record and no post-reconstitution stability window to track. What that leaves a laboratory to control is storage — capsule shells draw moisture from the air, so the container should be kept sealed and dry rather than decanted into an open vessel.
Because the material is already at its labelled quantity per capsule, batch verification carries more weight in this format than it does for powder: there is no point at which the researcher independently confirms mass by weighing. The measured content published for each lot is the figure that answers that question.
- 1 × sealed capsule bottle (10mg per capsule / Single Bottle - Pack of 60), batch-labelled
- Batch documentation for the lot shipped, once its certificate is published
- Discreet outer packaging with no product names on the exterior
- FedEx, tracked, typically 1–3 business days domestically
- Laboratory consumables of any kind
- Dosing, administration or protocol guidance of any kind
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each capsule contains the labeled quantity of SLU-PP-915. Independent third-party analysis verifies purity, identity, and net content per batch.
The container holds only the capsules. Any laboratory materials required for extraction, solubilisation, or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915
PubMedNovel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function
PubMedAn orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity
PubMedIn Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential
PubMed[Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications]
PubMedNuclear Receptor-Targeted Therapies: Reprogramming Metabolism with TRβ, ERRα, and LXR Modulators
PubMedRelated
You May Also Like
Fisetin-Derived Research Compound CMS-121 is a synthetic small molecule derived from the plant flavonoid fisetin, produced for laboratory research use only. It is supplied in capsule form for controlled experimental work and is not intended for any other application.
$29.99
Methylated Beta-Carboline Alkaloid 9-Me-BC (9-methyl-beta-carboline) is a small methylated beta-carboline alkaloid studied in neurochemical research models. It is supplied in capsule form strictly for laboratory research use.
$64.99
Uncharacterised Research Compound Compound-7P is supplied as capsules for laboratory research use. The designation "Compound-7P" is a non-systematic label and does not correspond to a single identified chemical entity in the published chemical or pharmacological literature. No PubChem record matches the name, and no molecular formula, sequence or structural profile was supplied with it.
$49.99
Redox-Active Flavin Analogue 5-Deazaflavin is a synthetic analogue of the flavin ring system in which the nitrogen at position 5 of the isoalloxazine core is replaced by carbon. The parent heterocycle (C11H7N3O2, MW 213.19) and its substituted derivatives are produced for laboratory research and are handled within controlled experimental environments.
$59.99